Presentations will evaluate the performance of the company’s pTau217 and pTau181 assays while also highlighting phase 3 clinical research for the investigational therapy trontinemab for Alzheimer’s disease.
Roche announced it will present 18 oral and poster presentations from its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference (AAIC) 2026 in London from July 12-15. The data focus on the development of diagnostic tests and medicines intended to detect and intervene in the progression of the disease.
The company will present data on the Elecsys pTau217 blood test, which recently received CE mark certification as a rule-in and rule-out test for amyloid pathology. Presentations will evaluate the performance of the test in both primary and secondary care settings. Additionally, Roche will share data on the Elecsys pTau181 blood test, focusing on sample stability under various storage conditions and test performance across diverse patient populations with cognitive impairment.
“With the approval of Elecsys pTau217, our third Alzheimer’s blood test, across both primary and secondary care, we are making timely and definitive diagnosis more accessible than ever before,” says Matt Sause, CEO of Roche Diagnostics, in a release. “For too long, this has been out of reach for the vast majority of patients. As a result, millions have been left without the answers, care, and support they need. That is now changing, as blood-based testing transforms the diagnosis of Alzheimer’s disease.”
Clinical Trial and Pharmaceutical Research
Research presentations will also feature trontinemab, an investigational bispecific amyloid-beta targeting monoclonal antibody. Roche will share long-term safety, amyloid removal, and biomarker data from a phase 1b/2a study.
The company will also share the design of the phase 3 PrevenTRON study, which is investigating trontinemab in preclinical Alzheimer’s disease. The study plans to recruit cognitively unimpaired individuals at high risk of progressing to symptomatic Alzheimer’s. Investigators are using the Elecsys pTau217 blood test to help identify potential participants for this study.
Neuroimmune Targets and Biomarkers
Other sessions will cover neuroimmune targets, including the NLRP3 inflammasome. Roche will present preclinical and clinical data regarding the effects of NLRP3 inhibition in neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease.
Additional diagnostic presentations will include data on the concordance of Elecsys cerebrospinal fluid biomarker ratios with amyloid-positron emission tomography in a Chinese population and the performance of the Elecsys pTau181 plasma immunoassay across different clinical stages.
“We aim to bring together advanced diagnostics and transformative medicines, with the goal of benefitting many Alzheimer’s patients through earlier detection and intervention,” says Levi Garraway, MD, PhD, Roche’s chief medical officer and head of global product development, in a release.
Roche is also sponsoring a symposium focused on the role of blood-based biomarkers in early detection and the use of scalable testing to reduce diagnostic barriers in clinical practice.
ID 76159822 © Jetcityimage | Dreamstime.com
